Amicus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amicus Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. 

CEO
Bradley Lewis Campbell
CEOBradley Lewis Campbell
Employees
499
Employees499
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
2002
Founded2002
Employees
499
Employees499

FOLD Key Statistics

Market cap
4.48B
Market cap4.48B
Price-Earnings ratio
-319.69
Price-Earnings ratio-319.69
Dividend yield
Dividend yield
Average volume
6.30M
Average volume6.30M
High today
$14.30
High today$14.30
Low today
$14.28
Low today$14.28
Open price
$14.29
Open price$14.29
Volume
7.69M
Volume7.69M
52 Week high
$14.38
52 Week high$14.38
52 Week low
$5.51
52 Week low$5.51

Stock Snapshot

Amicus Therapeutics(FOLD) stock is priced at $14.29, giving the company a market capitalization of 4.48B. It carries a P/E multiple of -319.69.

As of 2026-02-02, Amicus Therapeutics(FOLD) stock has fluctuated between $14.28 and $14.30. The current price stands at $14.29, placing the stock +0.1% above today's low and -0.1% off the high.

The Amicus Therapeutics(FOLD)'s current trading volume is 7.69M, compared to an average daily volume of 6.3M.

In the last year, Amicus Therapeutics(FOLD) shares hit a 52-week high of $14.38 and a 52-week low of $5.51.

In the last year, Amicus Therapeutics(FOLD) shares hit a 52-week high of $14.38 and a 52-week low of $5.51.

FOLD News

Simply Wall St 4d
Is It Time To Reassess Amicus Therapeutics After Last Year’s 48.9% Gain?

If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value today, the key is to look past the share price and focus on what the...

Is It Time To Reassess Amicus Therapeutics After Last Year’s 48.9% Gain?

Analyst ratings

100%

of 7 ratings
Buy
0%
Hold
100%
Sell
0%

People also own

Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.